The verdict: Celebrex stays

“Experts advising the agency on the future direction of Cox-2 pain drugs, including Vioxx, Celebrex, and Bextra, voted 31 to 1 to recommend that the drug stay on the market. But the panel has not yet addressed concerns that warnings or restrictions may be required to prevent patients from taking higher doses of the drug.”

Probably the right decision. The 200mg a day dose (which is the most common for arthritis) did not show increased heart risk.

Prev
Next